Author

K. L. Morel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

L. Ellis· 4 shared D. L. Burkhart· 3 shared A. A. Hamid· 2 shared A. V. Sheahan· 2 shared C. J. Sweeney· 2 shared J. N. Singh· 2 shared A. D. Choudhury· 1 shared A. G. Sowalsky· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

L. Ellis

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer

L. Ellis, B. German, J. N. Singh, D. L. Burkhart, A. Sheahan, H. Bergom, K. L. Morel, H. Beltran, J. Hwang, K. Lawrenson

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

bioRxiv · Jan 31, 2024 · PreprintCancer Biology

Loss of tristetraprolin activates NF-κB induced phenotypic plasticity and primes transition to lethal prostate cancer

K. L. Morel, A. A. Hamid, B. G. Falcon, J. N. Singh, S. Linder, A. M. Bergman, H. G. van der Poel, I. Hofland, E. M. Bekers, S. Trostel, S. Wilkinson, A. T. Ku, D. L. Burkhart, M. Kim, J. Kim, , L. Ellis

This study shows that loss of ZFP36 promotes NF-κB activation and phenotypic plasticity in prostate cancer, leading to aggressive disease and castration resistance, which can be reversed by NF-κB inhibition.

bioRxiv · Aug 5, 2022 · PreprintCancer Biology

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology

Targeting RET Kinase in Neuroendocrine Prostate Cancer

H. VanDeusen, J. R. Ramroop, K. L. Morel, A. V. Sheahan, Z. Sychev, N. A. Lau, L. C. Cheng, V. Tan, Z. Li, A. Petersen, J. K. Lee, J. Wook Park, R. Yang, I. Coleman, O. N. Witte, , J. M. Drake

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.

bioRxiv · Apr 29, 2019Cancer Biology